{"id":"NCT00419952","sponsor":"AstraZeneca","briefTitle":"A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.","officialTitle":"A 52-week, Randomised, Double-blind, Parallel-group, Multi-centre, Phase IIIB Study Comparing the Long Term Safety of SYMBICORT® pMDI 160/4.5 mg x 2 Actuations Twice Daily to Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily in Adult/Adolescent (≥12 Years) African American Subjects With Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2009-11","completion":"2009-11","firstPosted":"2007-01-09","resultsPosted":"2012-10-30","lastUpdate":"2012-10-30"},"enrollment":742,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Budesonide/formoterol (SYMBICORT) pMDI","otherNames":[]},{"type":"DRUG","name":"Budesonide HFA pMDI","otherNames":[]}],"arms":[{"label":"Symbicort","type":"EXPERIMENTAL"},{"label":"Budesonide","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.","primaryOutcome":{"measure":"Total Number of Asthma Exacerbations","timeFrame":"52 Weeks","effectByArm":[{"arm":"Symbicort","deltaMin":36,"sd":null},{"arm":"Budesonide","deltaMin":61,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":122,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.asthmaclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":377},"commonTop":["Headache","Nasopharyngitis","Sinusitis","Viral Upper Respiratory Tract Infection","Oropharyngeal Pain"]}}